前列腺特异性膜抗原PET/MRI在前列腺癌中的应用现状与前景

李慧; 杨志

doi:10.12290/xhyxzz.2021-0492

前列腺特异性膜抗原PET/MRI在前列腺癌中的应用现状与前景

doi: 10.12290/xhyxzz.2021-0492

李慧,
杨志^,

北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科国家药监局放射性药物研究与评价重点实验室恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142

基金项目:

北京大学肿瘤医院科学研究基金 2020-17

详细信息

通讯作者:
杨志，E-mail：pekyz@163.com

中图分类号: R445; R-1
计量
- 文章访问数: 671
- HTML全文浏览量: 165
- PDF下载量: 95
- 被引次数: 0
出版历程
- 收稿日期: 2021-06-25
- 录用日期: 2021-10-21
- 网络出版日期: 2021-10-26
- 刊出日期: 2022-03-30

Prostate Specific Membrane Antigen PET/MRI for the Management of Prostate Cancer: Current Status and Future Directions

LI Hui,
YANG Zhi^,

Department of Nuclear Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, Beijing 100142, China

Funds:

Science Foundation of Peking University Cancer Hospital 2020-17

More Information

Corresponding author: YANG Zhi, E-mail: pekyz@163.com

摘要

摘要: 前列腺癌(prostate cancer, PCa)是常见的老年男性恶性肿瘤，并是其主要致死原因之一。前列腺特异性膜抗原(prostate specific membrane antigen, PSMA)是一种PCa组织特异性高表达的跨膜蛋白，这使得PSMA成为PCa良好的特异性分子影像靶点。目前，PSMA PET/CT在PCa诊断、分期等方面的价值已被广泛认可。随着PET/MRI逐步进入临床，PSMA PET与MRI两种诊断PCa的重要影像学方法的有机结合成为可能。本文就PSMA PET/MRI在PCa中的应用现状与前景进行阐述，以期为临床诊疗提供借鉴。
- 前列腺癌 /
- 前列腺特异性膜抗原 /
- PET/MRI
Abstract: Prostate cancer (PCa) is one of the most common malignancies and one major leading cause of mortality from cancers in old men. Due to its specific overexpression in PCa cells, the prostate specific membrane antigen (PSMA) has become an ideal molecular imaging target for PCa.Currently, the value of PSMA PET/CT in the diagnosis and staging of PCa has been widely accepted. With the clinical application of simultaneous PET/MRI, it enables the possibility of combination of PSMA PET and MRI for the management of PCa. Here we present this review on the current status and future direction of the application of PSMA PET/MRI in the management of PCa.
- prostate cancer /
- prostate specific membrane antigen /
- PET/MRI
注释:

作者贡献：李慧负责查阅文献和论文撰写；杨志负责修订和审校论文。

利益冲突：所有作者均声明不存在利益冲突

HTML全文

参考文献(54)

[1]	DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older, 2019[J]. CA Cancer J Clin, 2019, 69: 452-467. doi: 10.3322/caac.21577
[2]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71: 7-33. doi: 10.3322/caac.21654
[3]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424. doi: 10.3322/caac.21492
[4]	付振涛, 郭晓雷, 张思维, 等. 2015年中国前列腺癌发病与死亡分析[J]. 中华肿瘤杂志, 2020, 42: 718-722. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201211003.htm Fu ZT, Guo XL, Zhang SW, et al. Statistical analysis of incidence and mortality of prostate cancer in China, 2015[J]. Zhonghua Zhongliu Zazhi, 2020, 42: 718-722. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201211003.htm
[5]	李星, 曾晓勇. 中国前列腺癌流行病学研究进展[J]. 肿瘤防治研究, 2021, 48: 98-102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLFY202101019.htm Li X, Zeng XY. Advances in Epidemiology of Prostate Cancer in China[J]. Zhongliu Fangzhi Yanjiu, 2021, 48: 98-102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLFY202101019.htm
[6]	顾秀瑛, 郑荣寿, 张思维, 等. 2000—2014年中国肿瘤登记地区前列腺癌发病趋势及年龄变化分析[J]. 中华预防医学杂志, 2018, 52: 586-592. Gu XY, Zheng RS, Zhang SW, et al. Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014[J]. Zhonghua Yufang Yixue Zazhi, 2018, 52: 586-592.
[7]	Hoffmann MA, Wieler HJ, Baues C, et al. The Impact of ⁶⁸Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer[J]. Urology, 2019, 130: 1-12. doi: 10.1016/j.urology.2019.04.004
[8]	Muller BG, Shih JH, Sankineni S, et al. Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging[J]. Radiology, 2015, 277: 741-750. doi: 10.1148/radiol.2015142818
[9]	熊诗诗, 吴介恒, 韩东晖, 等. 针对前列腺特异性膜抗原的抗体靶向治疗研究进展[J]. 细胞与分子免疫学杂志, 2017, 33: 278-282. https://www.cnki.com.cn/Article/CJFDTOTAL-XBFM201702029.htm
[10]	Fendler WP, Calais J, Eiber M, et al. Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial[J]. JAMA Oncol, 2019, 5: 856-863. doi: 10.1001/jamaoncol.2019.0096
[11]	Calais J, Ceci F, Eiber M, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial[J]. Lancet Oncol, 2019, 20: 1286-1294. doi: 10.1016/S1470-2045(19)30415-2
[12]	Liu C, Liu T, Zhang N, et al. (68)Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 1852-1861. doi: 10.1007/s00259-018-4037-9
[13]	Afshar-Oromieh A, Haberkorn U, Hadaschik B, et al. PET/MRI with a ⁶⁸Ga-PSMA ligand for the detection of prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2013, 40: 1629-1630. doi: 10.1007/s00259-013-2489-5
[14]	卢洁, 张苗, 方继良, 等. 一体化PET/MR颅脑成像检查规范(2017版)[J]. 中国医学影像技术, 2017, 33: 791-794. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201705050.htm Lu J, Zhang M, Fang JL, et al. Guidelines for hybrid PET/MR in brain imaging (2017 Edition)[J]. Zhongguo Yixue Yingxiang Jishu, 2017, 33: 791-794. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201705050.htm
[15]	Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging[J]. Radiology, 2011, 261: 46-66. doi: 10.1148/radiol.11091822
[16]	Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis[J]. N Engl J Med, 2018, 378: 1767-1777. doi: 10.1056/NEJMoa1801993
[17]	Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study[J]. Lancet, 2017, 389: 815-822. doi: 10.1016/S0140-6736(16)32401-1
[18]	Hamoen EHJ, de Rooij M, Witjes JA, et al. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis[J]. Eur Urol, 2015, 67: 1112-1121. doi: 10.1016/j.eururo.2014.10.033
[19]	Lee T, Hoogenes J, Wright I, et al. Utility of preoperative 3 Tesla pelvic phased-array multiparametric magnetic resonance imaging in prediction of extracapsular extension and seminal vesicle invasion of prostate cancer and its impact on surgical margin status: Experience at a Canadian academic tertiary care centre[J]. Can Urol Assoc J, 2017, 11: E174-E178. doi: 10.5489/cuaj.4211
[20]	Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues[J]. Clin Cancer Res, 1997, 3: 81-85.
[21]	Eiber M, Weirich G, Holzapfel K, et al. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer[J]. Eur Urol, 2016, 70: 829-836. doi: 10.1016/j.eururo.2015.12.053
[22]	Uprimny C, Kroiss AS, Decristoforo C, et al. (68)Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 941-949. doi: 10.1007/s00259-017-3631-6
[23]	Wang R, Shen G, Yang R, et al. (68)Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis[J]. Eur J Radiol, 2020, 130: 109131. doi: 10.1016/j.ejrad.2020.109131
[24]	Al-Bayati M, Grueneisen J, Lütje S, et al. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging[J]. Urol Int, 2018, 100: 164-171. doi: 10.1159/000484695
[25]	Thalgott M, Düwel C, Rauscher I, et al. One-Stop-Shop Whole-Body (68)Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer[J]. J Nucl Med, 2018, 59: 1850-1856. doi: 10.2967/jnumed.117.207696
[26]	Chen M, Zhang Q, Zhang C, et al. Combination of (68)Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis[J]. J Nucl Med, 2019, 60: 944-949. doi: 10.2967/jnumed.118.221010
[27]	Muehlematter UJ, Burger IA, Becker AS, et al. Diagnostic Accuracy of Multiparametric MRI versus (68)Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer[J]. Radiology, 2019, 293: 350-358. doi: 10.1148/radiol.2019190687
[28]	Grubmüller B, Baltzer P, Hartenbach S, et al. PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact[J]. Clin Cancer Res, 2018, 24: 6300-6307. doi: 10.1158/1078-0432.CCR-18-0768
[29]	Fendler WP, Schmidt DF, Wenter V, et al. ⁶⁸Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer[J]. J Nucl Med, 2016, 57: 1720-1725. doi: 10.2967/jnumed.116.172627
[30]	Domachevsky L, Bernstine H, Goldberg N, et al. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study[J]. Eur Radiol, 2020, 30: 328-336. doi: 10.1007/s00330-019-06353-y
[31]	Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis[J]. Clin Radiol, 2008, 63: 387-395. doi: 10.1016/j.crad.2007.05.022
[32]	Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer[J]. J Urol, 2016, 195: 1436-1443. doi: 10.1016/j.juro.2015.12.025
[33]	Uslu-Beşli I, Bakl B, Asa S, et al. Correlation of SUV(max) and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study[J]. Mol Imaging Radionucl Ther, 2019, 28: 104-111. doi: 10.4274/mirt.galenos.2019.63825
[34]	Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 2114-2121. doi: 10.1007/s00259-016-3435-0
[35]	Roach PJ, Francis R, Emmett L, et al. The Impact of (68)Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study[J]. J Nucl Med, 2018, 59: 82-88. doi: 10.2967/jnumed.117.197160
[36]	Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. Comparison of PET/CT and PET/MRI hybrid systems using a ⁶⁸Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 887-897. doi: 10.1007/s00259-013-2660-z
[37]	Ferraro DA, Becker AS, Kranzbühler B, et al. Diagnostic performance of ⁶⁸Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study[J]. Eur J Nucl Med Mol Imaging, 2021, 48: 3315-3324. doi: 10.1007/s00259-021-05261-y
[38]	Lindenberg ML, Turkbey B, Mena E, et al. Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review[J]. JAMA Oncol, 2017, 3: 1415-1422. doi: 10.1001/jamaoncol.2016.5840
[39]	Suardi N, Gandaglia G, Gallina A, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years[J]. Eur Urol, 2015, 67: 299-309. doi: 10.1016/j.eururo.2014.02.011
[40]	Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy[J]. J Nucl Med, 2015, 56: 668-674. doi: 10.2967/jnumed.115.154153
[41]	Hijazi S, Meller B, Leitsmann C, et al. See the unseen: Mesorectal lymph node metastases in prostate cancer[J]. Prostate, 2016, 76: 776-780. doi: 10.1002/pros.23168
[42]	Kranzbühler B, Nagel H, Becker AS, et al. Clinical performance of (68)Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 20-30. doi: 10.1007/s00259-017-3850-x
[43]	Kranzbühler B, Müller J, Becker AS, et al. Detection Rate and Localization of Prostate Cancer Recurrence Using (68)Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL[J]. J Nucl Med, 2020, 61: 194-201. doi: 10.2967/jnumed.118.225276
[44]	Joshi A, Roberts MJ, Perera M, et al. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial[J]. Clin Exp Metastasis, 2020, 37: 551-560. doi: 10.1007/s10585-020-10043-1
[45]	Freitag MT, Radtke JP, Afshar-Oromieh A, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 776-787. doi: 10.1007/s00259-016-3594-z
[46]	Guberina N, Hetkamp P, Ruebben H, et al. Whole-Body Integrated[(68)Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference[J]. Mol Imaging Biol, 2020, 22: 788-796. doi: 10.1007/s11307-019-01424-4
[47]	Turkbey B, Brown AM, Sankineni S, et al. Multipara-metric prostate magnetic resonance imaging in the evaluation of prostate cancer[J]. CA Cancer J Clin, 2016, 66: 326-336. doi: 10.3322/caac.21333
[48]	Abufaraj M, Grubmüller B, Zeitlinger M, et al. Prospec-tive evaluation of the performance of[(68)Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 2169-2177. doi: 10.1007/s00259-019-04361-0
[49]	Vargas HA, Wassberg C, Akin O, et al. MR imaging of treated prostate cancer[J]. Radiology, 2012, 262: 26-42. doi: 10.1148/radiol.11101996
[50]	Hötker AM, Mazaheri Y, Zheng J, et al. Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI[J]. Eur Radiol, 2015, 25: 2665-2672. doi: 10.1007/s00330-015-3688-1
[51]	Eisenhauer EA, Therasse P, Bogaerts J, et al. New res-ponse evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45: 228-247. doi: 10.1016/j.ejca.2008.10.026
[52]	Messiou C, Cook G, deSouza NM. Imaging metastatic bone disease from carcinoma of the prostate[J]. Br J Cancer, 2009, 101: 1225-1232. doi: 10.1038/sj.bjc.6605334
[53]	Barbosa FG, Queiroz MA, Nunes RF, et al. Clinical perspectives of PSMA PET/MRI for prostate cancer[J]. Clinics (Sao Paulo), 2018, 73: e586s.
[54]	Burger IA, Müller J, Donati OF, et al. (68)Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU[J]. J Nucl Med, 2019, 60: 1118-1123. doi: 10.2967/jnumed.118.221564

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 671
HTML全文浏览量: 165
PDF下载量: 95
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

前列腺特异性膜抗原PET/MRI在前列腺癌中的应用现状与前景

doi: 10.12290/xhyxzz.2021-0492

通讯作者:
杨志，E-mail：pekyz@163.com

计量

Prostate Specific Membrane Antigen PET/MRI for the Management of Prostate Cancer: Current Status and Future Directions

Corresponding author: YANG Zhi, E-mail: pekyz@163.com

计量

目录

留言板

前列腺特异性膜抗原PET/MRI在前列腺癌中的应用现状与前景

doi: 10.12290/xhyxzz.2021-0492

通讯作者: 杨志，E-mail：pekyz@163.com

计量

出版历程

Prostate Specific Membrane Antigen PET/MRI for the Management of Prostate Cancer: Current Status and Future Directions

Corresponding author: YANG Zhi, E-mail: pekyz@163.com

计量

出版历程

目录

通讯作者:
杨志，E-mail：pekyz@163.com